There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals Inc (ALNA – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report) with bullish sentiments.
Allena Pharmaceuticals Inc (ALNA)
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Allena Pharmaceuticals Inc. The company’s shares opened today at $7.27.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 29.2% and a 53.2% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Scholar Rock Holding Corp, and Intra-Cellular Therapies.
Currently, the analyst consensus on Allena Pharmaceuticals Inc is a Strong Buy with an average price target of $27, which is a 271.4% upside from current levels. In a report issued on March 8, B.Riley FBR also reiterated a Buy rating on the stock with a $22 price target.
Lexicon Pharmaceuticals (LXRX)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Lexicon Pharmaceuticals, with a price target of $38. The company’s shares opened today at $7.35.
According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.0% and a 37.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lexicon Pharmaceuticals with a $19.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.